Login to Your Account

Clinic Roundup

Monday, October 7, 2013
• Curis Inc., of Lexington, Mass., said partner Roche AG, of Basel, Switzerland, began a Phase Ib/II study with Erivedge (vismodegib) in patients with relapsed/ refractory acute myelogenous leukemia and relapsed/refractory high-risk myelodysplastic syndrome.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription